Related Experiment Videos
PPAR gamma/RXR as a molecular target for diabetes
1Department of Metabolic Diseases, GlaxoSmithKline Inc., 5 Moore Drive, Research Triangle Park, North Carolina 27709, USA.
Receptors & Channels
|November 8, 2001
Summary
Novel therapies targeting nuclear receptors peroxisome proliferator activating receptor gamma (PPAR gamma) and retinoid X receptor (RXR) show promise for improving insulin action and metabolic abnormalities in type 2 diabetes.
Area of Science:
- Endocrinology and Metabolism
- Molecular Biology
- Pharmacology
Background:
- Type 2 diabetes is characterized by insulin resistance in peripheral tissues.
- Nuclear receptors peroxisome proliferator activating receptor gamma (PPAR gamma) and retinoid X receptor (RXR) are key targets for novel diabetes therapies.
- PPAR gamma/RXR heterodimers regulate genes involved in insulin sensitivity, lipid metabolism, and inflammation.
Purpose of the Study:
- To review recent developments in research on PPAR gamma and RXR.
- To emphasize the metabolic effects, ligand selectivity, structure, and regulation of the PPAR gamma/RXR heterodimer.
Main Methods:
- Review of recent scientific literature on PPAR gamma and RXR.
- Analysis of selective ligands and their impact on metabolic abnormalities.
- Examination of factors influencing PPAR gamma/RXR heterodimer activity.
Main Results:
- Selective ligands for PPAR gamma/RXR improve hyperglycemia, hyperlipidemia, and insulin resistance.
- Adipose tissue and other tissues mediate the effects of these ligands.
- Heterodimer activity is modulated by posttranslational modifications, receptor turnover, polymorphisms, splice variants, coactivators, and corepressors.
Conclusions:
- Targeting PPAR gamma and RXR offers a promising therapeutic strategy for type 2 diabetes.
- Understanding the complex regulation of the PPAR gamma/RXR heterodimer is crucial for developing effective treatments.